Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in the Oppenheimer 25th Annual Healthcare Life Sciences Conference. The company will engage in a fireside chat scheduled for February 11, 2025, at 2:40 p.m. ET.

The presentation will be accessible via webcast through the Investors section of Voyager's website at ir.voyagertherapeutics.com. Interested parties can access a replay of the webcast, which will remain available on the company's website for a minimum of 30 days following the presentation.

News Market Reaction – VYGR

-1.06%

-1.06% Session move

In the trading session that priced this news, VYGR declined 1.06%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25^th Annual Healthcare Life Sciences Conference at 2:40 p.m. ET on February 11, 2025.

A webcast of the presentation will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the Company’s website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Contacts

Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Mike Hencke, mhencke@kendallir.com   
Media: Brooke Shenkin, brooke@scientpr.com

FAQ

When is Voyager Therapeutics (VYGR) presenting at the Oppenheimer Healthcare Conference 2025?

Voyager Therapeutics will present at the Oppenheimer Healthcare Conference on February 11, 2025, at 2:40 p.m. ET.

How can investors access Voyager Therapeutics' (VYGR) Oppenheimer Conference presentation?

Investors can access the presentation webcast through Voyager's investor relations website at ir.voyagertherapeutics.com.

How long will the replay of VYGR's Oppenheimer Conference presentation be available?

The webcast replay will be archived on Voyager Therapeutics' website for at least 30 days after the presentation.

What type of presentation will VYGR deliver at the 2025 Oppenheimer Healthcare Conference?

Voyager Therapeutics will participate in a fireside chat format presentation at the conference.